GlaxoSmithKline (CAI:BIOC) Total Equity: E£1,072 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Total Equity?

GlaxoSmithKline CAI:BIOC +1.62% Total Equity is E£1,072 Mil as of Sep. 2016.

GlaxoSmithKline's total equity for the quarter that ended in Sep. 2016 was E£1,072 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

GlaxoSmithKline Total Equity Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Total Equity Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Total Equity
977.92 985.84 980.93 1,002.83

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 802.33 1,002.83 929.91 968.22 1,071.97

GlaxoSmithKline Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GlaxoSmithKline's Total Equity for the fiscal year that ended in Dec. 2015 is calculated as

Total Equity=Total Assets(Q: Dec. 2015 )-Total Liabilities(Q: Dec. 2015 )
=1766.511-763.685
=1,003

GlaxoSmithKline's Total Equity for the quarter that ended in Sep. 2016 is calculated as

Total Equity=Total Assets(Q: Sep. 2016 )-Total Liabilities(Q: Sep. 2016 )
=1880.786-808.814
=1,072

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of E£1,072 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Total Equity of E£1,072 Mil as of Sep. 2016. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Total Equity too high?
GlaxoSmithKline's current Total Equity is E£1,072 Mil.
How does GlaxoSmithKline's Total Equity compare to PRPH?
GlaxoSmithKline's Total Equity of E£1,072 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors. GlaxoSmithKline's current Total Equity is E£1,072 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Total Equity of E£1,072 Mil. The current Total Equity is E£1,072 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Total Equity is E£1,072 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.